ArticleDevice2025
A radically simple, ingestible colorimetric biosensor pill for cost-effective, non-invasive monitoring of intestinal inflammation.
Article in Device, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Current approaches to disease severity and therapy effectiveness assessment in patients with inflammatory bowel disease.World journal of gastrointestinal pharmacology and therapeutics · 2026Review
- An Edible HAdvanced healthcare materials · 2026Article
- Immunomodulatory biomaterials as a novel therapeutic platform for inflammatory bowel disease.Therapeutic advances in gastroenterology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Inflammatory bowel diseases (IBDs) affect millions worldwide, necessitating frequent monitoring of intestinal inflammation to optimize treatment strategies. However, current fecal calprotectin tests have low patient adherence, limiting their utility for inflammation monitoring. Here, we developed an ingestible biosensor for simplified at-home detection of a key inflammation biomarker-reactive oxygen species (ROS). Our pill for ROS-responsive inflammation monitoring (PRIM) employs an ROS-responsive polymer that selectively degrades in the presence of ROS. Degradation triggers the release of blue dye into feces for a visually detectable readout without fecal sampling or laboratory analysis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.